Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Rosenberg, O., Isserles, M., Levkovitz, Y., Kotler, M., Zangen, A., & Dannon, P. N. (2011). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(4), 1041-1044.
This study examined the effect of the Brainsway® Deep TMS (Transcranial Magnetic Stimulation) H-coil stimulation on depressed patients which previously benefited from the treatment but suffered from deterioration. The patients were given 20 daily sessions of stimulation, resulting in a significant decrease in HDRS, HARS and BDI scores, although at a lesser rate compared to the decrease during the first Deep TMS treatment period. In this study it was demonstrated that a second treatment period of brain stimulation using the H-coil significantly alleviates depressive symptoms.